Literature DB >> 26361407

Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials.

Alessandro Paniccia1, Justin Merkow1, Barish H Edil1, Yuwen Zhu1.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death and current therapeutic strategies are often unsatisfactory. Identification and development of more efficacious therapies is urgently needed. Immunotherapy offered encouraging results in preclinical models during the last decades, and several clinical trials have explored its therapeutic application in PDAC. The aim of this review is to summarize the results of clinical trials conducted to evaluate the future perspective of immunotherapy in the treatment of PDAC.

Entities:  

Keywords:  Immunotherapy; cancer vaccines; clinical trial; pancreatic neoplasm

Year:  2015        PMID： 26361407      PMCID： PMC4560736          DOI： 10.3978/j.issn.1000-9604.2015.05.01

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN： 1000-9604            Impact factor:   5.087


  125 in total

Review 1.  Dendritic cells: specialized and regulated antigen processing machines.

Authors:  I Mellman; R M Steinman
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

2.  Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer.

Authors:  Hiroki Sakamoto; Hideharu Kimura; Masaru Sekijima; Kazuko Matsumoto; Tokuzo Arao; Takaaki Chikugo; Yasuhide Yamada; Masayuki Kitano; Akihiko Ito; Yoshifumi Takeyama; Masatoshi Kudo; Kazuto Nishio
Journal:  Jpn J Clin Oncol       Date:  2011-12-12       Impact factor: 3.019

3.  KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.

Authors:  Jianhua Ling; Ya'an Kang; Ruiying Zhao; Qianghua Xia; Dung-Fang Lee; Zhe Chang; Jin Li; Bailu Peng; Jason B Fleming; Huamin Wang; Jinsong Liu; Ihor R Lemischka; Mien-Chie Hung; Paul J Chiao
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

Review 4.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

5.  Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival.

Authors:  Graziella Bellone; Carlo Smirne; Francesco Angelo Mauri; Elena Tonel; Anna Carbone; Alessandra Buffolino; Luca Dughera; Antonio Robecchi; Mario Pirisi; Giorgio Emanuelli
Journal:  Cancer Immunol Immunother       Date:  2005-08-11       Impact factor: 6.968

Review 6.  Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.

Authors:  Vicki Huff
Journal:  Nat Rev Cancer       Date:  2011-01-20       Impact factor: 60.716

Review 7.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

8.  Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.

Authors:  Ramesh K Ramanathan; Kenneth M Lee; John McKolanis; Elizabeth Hitbold; Wolfgang Schraut; Arthur J Moser; Elizabeth Warnick; Theresa Whiteside; Jennifer Osborne; Hyoung Kim; Roger Day; Monica Troetschel; Olivera J Finn
Journal:  Cancer Immunol Immunother       Date:  2004-09-14       Impact factor: 6.968

Review 9.  The anticancer immune response: indispensable for therapeutic success?

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Fabrice André; Antoine Tesniere; Guido Kroemer
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

10.  A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer.

Authors:  Nobuaki Suzuki; Shoichi Hazama; Tomio Ueno; Hiroto Matsui; Yoshitaro Shindo; Michihisa Iida; Kiyoshi Yoshimura; Shigefumi Yoshino; Kazuyoshi Takeda; Masaaki Oka
Journal:  J Immunother       Date:  2014-01       Impact factor: 4.456
View more
  11 in total

Review 1.  Targeting reactive oxygen species in development and progression of pancreatic cancer.

Authors:  Nisha Durand; Peter Storz
Journal:  Expert Rev Anticancer Ther       Date:  2016-11-23       Impact factor: 4.512

2.  Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.

Authors:  Quisette P Janssen; Stefan Buettner; Mustafa Suker; Berend R Beumer; Pietro Addeo; Philippe Bachellier; Nathan Bahary; Tanios Bekaii-Saab; Maria A Bali; Marc G Besselink; Brian A Boone; Ian Chau; Stephen Clarke; Mary Dillhoff; Bassel F El-Rayes; Jessica M Frakes; Derek Grose; Peter J Hosein; Nigel B Jamieson; Ammar A Javed; Khurum Khan; Kyu-Pyo Kim; Song Cheol Kim; Sunhee S Kim; Andrew H Ko; Jill Lacy; Georgios A Margonis; Martin D McCarter; Colin J McKay; Eric A Mellon; Sing Yu Moorcraft; Ken-Ichi Okada; Alessandro Paniccia; Parag J Parikh; Niek A Peters; Hans Rabl; Jaswinder Samra; Christoph Tinchon; Geertjan van Tienhoven; Eran van Veldhuisen; Andrea Wang-Gillam; Matthew J Weiss; Johanna W Wilmink; Hiroki Yamaue; Marjolein Y V Homs; Casper H J van Eijck; Matthew H G Katz; Bas Groot Koerkamp
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

3.  Deeper insights into long-term survival heterogeneity of pancreatic ductal adenocarcinoma (PDAC) patients using integrative individual- and group-level transcriptome network analyses.

Authors:  Archana Bhardwaj; Claire Josse; Daniel Van Daele; Christophe Poulet; Marcela Chavez; Ingrid Struman; Kristel Van Steen
Journal:  Sci Rep       Date:  2022-06-30       Impact factor: 4.996

4.  Immune Cells Combined With NLRP3 Inflammasome Inhibitor Exert Better Antitumor Effect on Pancreatic Ductal Adenocarcinoma.

Authors:  Hailiang Liu; Yong Xu; Kai Liang; Rong Liu
Journal:  Front Oncol       Date:  2020-08-21       Impact factor: 6.244

5.  Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression.

Authors:  Jianqin Lu; Xiangsheng Liu; Yu-Pei Liao; Felix Salazar; Bingbing Sun; Wen Jiang; Chong Hyun Chang; Jinhong Jiang; Xiang Wang; Anna M Wu; Huan Meng; Andre E Nel
Journal:  Nat Commun       Date:  2017-11-27       Impact factor: 14.919

6.  Pancreatic cancer cell/fibroblast co-culture induces M2 like macrophages that influence therapeutic response in a 3D model.

Authors:  Janina Kuen; Diana Darowski; Tobias Kluge; Meher Majety
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

7.  A Tumor-Selective Monoclonal Antibody from Immunization with a Tumor-Associated Mucin Glycopeptide.

Authors:  Kevin R Trabbic; Kaitlyn Whalen; Karin Abarca-Heideman; Li Xia; J Sebastian Temme; Elijah F Edmondson; Jeffrey C Gildersleeve; Joseph J Barchi
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

8.  Investigation of Polyamine Metabolism and Homeostasis in Pancreatic Cancers.

Authors:  Chelsea Massaro; Jenna Thomas; Otto Phanstiel Iv
Journal:  Med Sci (Basel)       Date:  2017-12-07

9.  Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma.

Authors:  Qingqing Liu; John Stewart; Hua Wang; Asif Rashid; Jun Zhao; Matthew H Katz; Jeffrey E Lee; Jason B Fleming; Anirban Maitra; Robert A Wolff; Gauri R Varadhachary; Sunil Krishnan; Huamin Wang
Journal:  PLoS One       Date:  2017-02-10       Impact factor: 3.752

Review 10.  Immunological combination treatment holds the key to improving survival in pancreatic cancer.

Authors:  M H Sodergren; N Mangal; H Wasan; A Sadanandam; V P Balachandran; L R Jiao; N Habib
Journal:  J Cancer Res Clin Oncol       Date:  2020-08-03       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.